Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18500827 | 0.95 | APP (0.43) | APPMEN1KMT2AACHEHPSE | |
| SCHEMBL16405614 | 0.92 | APP (0.46) | APPMEN1KMT2AHPSEBACE1 | |
| SCHEMBL16407191 | 0.92 | HRH3 (0.44) | APPMEN1KMT2AACHEBACE1 | |
| SCHEMBL16407044 | 0.91 | ACHE (0.47) | APPMEN1KMT2AACHERAD52 | |
| SCHEMBL16407043 | 0.91 | MEN1 (0.47) | APPMEN1KMT2AACHEBACE1 | |
| SCHEMBL16407040 | 0.91 | RAD52 (0.47) | APPMEN1KMT2AACHENR4A2 | |
| SCHEMBL16405607 | 0.91 | APP (0.42) | APPMEN1KMT2AHPSENR4A2 | |
| SCHEMBL16407193 | 0.88 | CYP3A4 (0.42) | APPACHEBACE1NR4A2 | |
| SCHEMBL18499171 | 0.88 | APP (0.42) | APPMEN1KMT2AHPSENR4A2 | |
| SCHEMBL18499170 | 0.87 | APP (0.44) | APPHPSENR4A2RAD52GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150023930-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023930-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | LRRK2, NLN, AADAT | APP 219/4885MEN1 1524/4885KMT2A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.